| 1 | Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer:trials and treatment options显示文摘During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in EGFR and translocations in ALK and ROS1 have identified subsets of patients with excellent tumor response to oral targeted agents with manageable side effects. In this review, we highlight treatment options including corresponding clinical trials for oncogenic alterations affecting the receptor tyrosine kinases MET, FGFR, NTRK, RET, HER2, HER3, and HER4 as well as components of the RAS-RAF-MEK signaling pathway. | Arpita Desai Smitha P.Menon Grace K.Dy | 2016 | Cancer Biology & Medicine2016，13，1： | 6 |
您所在的机构暂未开通此部分的功能，请联系管理员